ICARES Medicus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021
Share
ICARES Medicus, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 101.41 million compared to TWD 94.69 million a year ago. Net income was TWD 17.68 million compared to TWD 22.51 million a year ago. Basic earnings per share from continuing operations was TWD 0.53 compared to TWD 0.67 a year ago. Diluted earnings per share from continuing operations was TWD 0.52 compared to TWD 0.67 a year ago.
For the nine months, sales was TWD 280.85 million compared to TWD 290.84 million a year ago. Net income was TWD 32.4 million compared to TWD 52.63 million a year ago. Basic earnings per share from continuing operations was TWD 0.96 compared to TWD 1.57 a year ago. Diluted earnings per share from continuing operations was TWD 0.96 compared to TWD 1.56 a year ago.
Icares Medicus Inc is a Taiwan-based company mainly engaged in the authorization of high-end medical material surface treatment technology. The Company is also involved in the sale of surface treatment formulations and provision of customer surface treatment processing services, as well as the research and development, manufacture and sale of artificial lens and its implantation system. The Company's product revenue is mainly divided into three categories. The royalty income comes from the authorization of implantation/invasive high-end medical material surface treatment technology. The technical service income mainly includes implantation/invasive high-end medical surface treatment services, provision of medical coatings and foundry of artificial lens implantation systems. The sales of medical materials mainly include the sales of medical materials surface inspection equipment and other products. The Company distributes its products in domestic and overseas markets.
ICARES MEDICUS, INC. 
